Studies will be included that involve participants of any gender and age, with a molecular diagnosis of MPS IVA, along with a description and/or classification of the clinical phenotype.

The included studies must meet the following criteria:

The exclusion criteria are as follows:

This meta-analysis will encompass a broad range of study designs, incorporating both experimental and quasi-experimental methodologies. Experimental designs, such as randomized controlled trials, nonrandomized controlled trials, before-and-after studies, and interrupted time-series studies, will be included. Additionally, observational studies, including both prospective and retrospective cohort studies, case-control studies, and analytical cross-sectional studies, will be considered for inclusion.

Furthermore, various observational study designs, such as case series, individual case reports, and descriptive cross-sectional studies, will also be considered for inclusion in this review. Qualitative studies will be considered as well.

The search strategy has been designed to identify published studies exclusively in Spanish, English, and Portuguese regardless of the publication date. Key terms from article titles and abstracts, as well as index terms, have been used to formulate a comprehensive search strategy for various databases, including MEDLINE, Web of Science, the Cochrane Library, ScienceDirect, PubMed, and Scopus.

The Medical Subject Headings (MeSH) keywords used for the database search are as follows: (GALNS OR “galactosamine-6-sulfatase” OR “Mucopolysaccharidosis IV”) AND (“genetic variants” OR “genetic variations” OR “mutations”) AND (“clinical” OR “phenotype”).

The search will be conducted by a single reviewer, who will perform the search in the specified databases, adhering to the MeSH keywords outlined above.

The identified bibliography will be uploaded to the Covidence platform (Veritas Health Innovation Ltd), duplicates will be removed, and 3 reviewers will screen the literature based on the title and abstract. Subsequently, the full text will be analyzed to verify compliance with the inclusion criteria. Exclusion reasons will be categorized and reported in the systematic review. Any disagreements will be resolved by an additional reviewer or through consensus among the reviewers. The results will be presented in the final systematic review.

A data extraction instrument was created. A total of 2 researchers will extract the data from each record. Extraction fields include the following: the country where the study was conducted, year of publication, data characterization (physiopathology, diagnostic, epidemiology, management or treatment, and complications), study design, medical history, clinical diagnosis, diagnostic test and results, and clinical interventions. Any disagreements that arise between the reviewers at each stage of the selection process will be resolved through discussion or with an additional reviewer.

A descriptive tabulation of the necessary information will be conducted to establish the genotype-phenotype relationship in patients with MPS IVA, encompassing epidemiology, physiopathology, and genetic diagnosis. Data will be analyzed using IBM SPSS Statistics software. The genotype-phenotype association will be assessed using chi-square or Fisher exact tests and/or regression analysis. The entirety of gathered knowledge will be summarized and discussed, taking into consideration the limitations of the review.

Compound heterozygous variants will not be considered in the genotype-phenotype analysis due to the inherent complexity of interactions between these variants. However, they will be individually described and discussed, aiming to establish a precedent for future research and publications in the field.

Furthermore, in the event of discrepancies in the phenotypes of homozygous patients carrying the same variant, the authors of the original publications will be contacted to investigate potential factors that may contribute to this variability, such as age at diagnosis and the use of enzyme replacement therapy. Each finding will be discussed in detail.

Snowballing or citation tracking criteria will be applied to identify significant articles pertinent to the research topic. This process will involve utilizing the reference list of a paper or citations of a paper by other articles to uncover additional manuscripts relevant to the study’s subject. Once potential new manuscripts and citations are identified, a backward snowballing search will be conducted by scrutinizing the reference list and excluding papers that do not meet the basic inclusion criteria. Subsequently, previously examined papers from the list will be eliminated. If a paper aligns with the inclusion criteria, potential new manuscripts will be pinpointed by reviewing the reference list of the included paper [12]. Subsequently, forward snowballing will be conducted, identifying new papers from the reference list of included papers, utilizing a method like backward snowballing.

This exploratory review aims to categorize the phenotypic severity of patients with MPS IVA and associate these phenotypes with specific genotypes. By mapping each pathogenic variant onto the GALNS protein structure, the analysis will evaluate how these variants in different domains and regions of the protein influence disease severity. This approach will help identify patterns of pathogenic variants associated with varying levels of clinical severity, providing key insights into how the location and type of variant affect GALNS functionality and the overall severity of MPS IVA. The findings will offer a deeper understanding of genotype-phenotype relationships, with potential to guide future diagnostic and therapeutic approaches.

The meta-analysis is expected to demonstrate the relationship between the type of genetic variation and its location in the GALNS protein and the severity of the phenotype in patients with MPS IVA.

The relationship between GALNS variants and their impact on pathophysiology, severity, and treatment opportunities is a well-studied topic. Several investigations have explored the genotype-phenotype relationship, such as the study by Zanetti et al [7], which included 314 patients with 135 different variants. Of these variants, 103 were associated with a severe phenotype, 19 with a nonsevere phenotype, 2 with an intermediate phenotype, and 11 with conflicting clinical phenotypes. According to the authors, the inconsistency in phenotype-genotype classification could be attributed to the heterogeneity of the disease and the varying ages of the patients at diagnosis [7].

Additionally, studies such as Yi et al [13] found 82 patients with a severe phenotype, 14 with an intermediate phenotype, and 12 with an attenuated phenotype. The classification included both homozygous and compound heterozygous patients and was based on the type of variants and their location in the protein [13].

Furthermore, some identified variants have even led to the identification of new clinical variations that have led to the reporting of new cases, such as the one identified by Ge et al [14] that establishes a relationship between neurogenic bladder and MPS IV.

Among the findings on the correlation between genotype or genetic variations in mutations and the patient’s phenotypic presentation, studies such as Tomatsu et al [15] stand out. The authors proposed that some genetic variations in conserved regions directly affect the enzyme’s functional capacity and lead to specific phenotypic alterations that require a more in-depth intervention process in patients with MPS IVA [15]. Other studies, such as Jezela-Stanek et al [16], found that phenotype-genotype assessment and correlation have been shown to predict aspects related to anthropometric measurements and associated complications.

On the other hand, this meta-analysis presents several limitations, including variations in phenotype severity that are independent of genotype. For instance, enzyme replacement therapy, designed to mitigate disease progression, may influence the outcomes. Additionally, age differences are a significant factor, particularly in patients diagnosed at early stages, where clinical characteristics may not yet be fully developed. Furthermore, in compound heterozygous patients, it is challenging to establish a precise relationship between genotype and phenotype, as the final characteristics will be affected by the interaction of both variants.

Understanding the relationship between variant types, protein mutation location, and patient phenotypes will enhance our comprehension of which protein sites and types of variants have the greatest impact on the pathophysiology of MPS IVA. This knowledge will not only aid in predicting disease severity in new cases but also facilitate more precise monitoring of disease progression, serving as a marker for complications associated with Morquio A syndrome. These insights will have broader implications for guiding medical interventions, allowing for greater precision and effectiveness in treatment strategies.